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A growing number of mutations in PIK3R1, the gene that encodes for the p85a regulatory subunit of PI3K,
have been recently identified. In this issue of Cancer Cell, Cheung and colleagues describe two neomorphic
PIK3R1mutants prevalent in endometrial and colon cancer that induce transformation via activation of PI3K-
independent pathways.With advances in sequencing technology,
a rapidly growing amount of genomic
profiling data is publicly available. How-
ever, the functional importance of the
majority of observed mutations remains
unclear. A growing challenge is to
characterize the biological effects of
each of the specificmutations, even those
occurring in genes whose functions have
been previously well characterized. In
general, mutations are classified into
three categories: hypomorphic, those
that decrease function; hypermorphic,
those that increase function; and neomor-
phic, those that confer a novel function.
IDH1 and IDH2 mutations are well-estab-
lished examples of neomorphic mutations
in which the mutant enzymes catalyze a
reaction not performed by the wild-type
enzyme (Dang et al., 2009; Cairns and
Mak, 2013).
In this issue ofCancer Cell, Cheung et al.
(2014) describe two neomorphicmutations
in PIK3R1 identified by sequencing ana-
lyses of endometrial and colon cancers.
In general, somatic mutations in PIK3R1
are prevalent in endometrial carcinoma
(33.8%), metastatic prostate adenocarci-
noma (11.5%), glioblastoma (11%), and
colorectal adenocarcinoma (9.7%) (http://
www.cbioportal.org). The specific muta-
tions discussed by Cheung et al. (2014),
PIK3R1R348* and PIK3R1L370fs, add to a
growing number of specific PIK3R1muta-
tions that impact intracellular signaling
via distinct molecular mechanisms (see
below). PIK3R1 encodes for the p85a reg-
ulatory subunit of PI3K, a lipid kinase
that converts phosphatidylinositol (4,5)-bi-
sphosphate (PIP2) into phosphatidyli-
nositol (3,4,5)-trisphosphate (PIP3) in the
plasma membrane. PIP3, in turn, activates
downstreamproteins, such asAKT, to pro-
mote cell growth and survival (Engelman,
2009). PI3K signaling is negatively regu-lated by the phosphatase PTEN, which de-
phosphorylates PIP3 back to PIP2. The
PI3K holoenzyme is comprised of a cata-
lytic subunit (p110a, b, g, and d) and a
regulatory subunit (p85a and b). The bind-
ing of p85a to p110 both stabilizes the
holoenzyme and inhibits p110 catalytic
activity until the activation of the kinase
is specifically triggered by the binding
of the p85 SH2 domains to phosphotyro-
sine peptides (Figure 1A). p85a also
binds PTEN (Chagpar et al., 2010), pre-
venting PTEN ubiquitination and degrada-
tion and thus increasing the stability of
the phosphatase (Cheung et al., 2011)
(Figure 1A).
To functionally characterize the two new
mutants, PIK3R1R348* and PIK3R1L370fs,
the sensitivity of BaF3 cells transformed
by each mutant was assessed against a
panel of inhibitors. Unexpectedly, the au-
thors observed heightened sensitivity to
MEK and JNK pathway inhibitors. Indeed,
these mutants led to activation of the ERK
and JNK pathways in cells and human
cancer specimens. These findings were
distinct from other PIK3R1 mutations,
which did not activate the ERK and JNK
pathways or result in heightened sen-
sitivity to inhibitors of these pathways,
suggesting a neomorphic function for
these two mutants. The PIK3R1R348* and
PIK3R1L370fs mutants encode p85a pro-
teins that are prematurely truncated within
the nSH2 domain and therefore lack the
iSH2 domain and do not bind p110a
(Figure 1A). Although these investigators
had previously demonstrated that expres-
sion of p85aR348* activates AKT signaling
(Cheung et al., 2011), the current study
demonstrates that the activation of the
MAPK pathways is independent of PI3K
signaling. Specifically, these p85a mu-
tants function as scaffolds that assemble
and stabilize a cytosolic complex thatCancer Cell 26includes JNK1, JNK2, Cdc42, Rac1,
MLK3, and MLK7. Once stabilized, this
complex translocates to the nucleus,
where activation of JNK signaling occurs.
The authors speculate that the intact
nSH2 domain present in the wild-type
p85amight prevent p85a from translocat-
ing into the nucleus; thus, the truncated
nSH2 domain confers a neomorphic func-
tion to these mutants. In contrast to the
mechanism of JNK activation, ERK is acti-
vated through a Cdc42/Rac1, B-RAF,
MKK1/2 signaling cascade in the cyto-
plasm. However, themechanismbywhich
the neomorphic p85a mutants activate
Cdc42/Rac1 requires further investiga-
tions. Of note, another report has demon-
strated that PI3K, through its canonical
lipid kinase activity, activates the RAF/
MEK/ERK signaling pathway via p-Rex1
and Rac1 in some luminal breast cancers
(Ebi et al., 2013).
The results from Cheung et al. (2014)
demonstrate that distinct mutations may
have different functional consequences
(Figures 1A and 1B). In endometrial carci-
nomas, the majority of p85a mutations
reside within the iSH2 domain (Cheung
et al., 2011). Some of these activate PI3K
signaling by disrupting the inhibitory con-
tact with the C2 domain of p110 (Wu
et al., 2009) (Figure 1A). Consistently,
BaF3 cells expressing iSH2 domain mu-
tants exhibit increased PI3K signaling,
cell survival, and tumorigenesis (Jaiswal
et al., 2009). Mutations are also relatively
frequent in the nSH2 domain, where
PIK3R1R348* and PIK3R1L370fs are located.
Although the current study demonstrated
that p85aR348* and p85aL370fs activate
ERK and JNK signaling as well as PI3K, it
remains unknown if other mutations in
the nSH2 domain will also activate these
MAPK pathways. Sun et al. (2010) showed
that distinct p85a nSH2 domain mutants, October 13, 2014 ª2014 Elsevier Inc. 445
AB
Figure 1. p85 Functions and Mutations
(A) Schematic representation of interactions between regulatory subunit p85a and catalytic subunit p110 of PI3K or between p85a and lipid phosphatase PTEN.
Labels mark the domains of the proteins. For p85, these are the SH3 domain, RhoGAP domain, N-terminal SH2 domain (nSH2), inter-SH2 domain (iSH2), and
C-terminal SH2 domain (cSH2). For p110, the domain designations are adaptor-binding domain (ABD), Ras-binding domain (RBD), C2 domain, helical domain,
and kinase domain. For p85, somemutations are graphedwith the amino acid indicated, and the percentage ofmutations identified in each domain in endometrial
cancer is shown above the domain.
(B) List of different p85a mutants and their ability to bind p110 and PTEN, to activate different pathways, and transforms cells. N/A not available.
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Previewstransform chicken embryo fibroblast with
markedly different efficiencies. In light of
the provocative results in the study by
Cheung et al. (2014), it would be inter-
esting to determine if differential effects
on ERK and JNK signaling underlie the
different oncogenic activity of these
distinct mutants. Finally, mutations have
also been observed in the RhoGAP
domain (Cheung et al., 2011). Since the
RhoGAP domain is involved in binding
PTEN (Chagpar et al., 2010), some mu-
tants in this domain, such as p85aE160*,
lose their ability to bind both p110 and
PTEN, leading to increased PI3K/AKT
signaling and transformation of BaF3 cells
(Cheung et al., 2011).
The therapeutic implications of the
various PIK3R1 mutations have yet to be
fully explored. For example, BaF3 cells
transformed by overexpression of the
iSH2 domain mutants are sensitive to
PI3K inhibitors (Jaiswal et al., 2009). How-
ever, it is unknown if real cancers harboring
these mutations are addicted to PI3K
signaling and would be sensitive to sin-
gle-agent PI3K pathway inhibitors. Along
similar lines, although the current study
demonstrates that ERK and JNK signaling446 Cancer Cell 26, October 13, 2014 ª2014are activated in endometrial carcinomas
harboring the PIK3R1R348* mutation, it re-
mains unknown if such cancers would be
sensitive to inhibitors of these pathways.
Although the authors demonstrate that a
MEK inhibitor slowed the growth of cancer
cells expressing p85aR348* more than
those with wild-type p85a, the impact
was only modest. It also remains possible
that cancers harboring this mutation may
be susceptible to PI3K pathway inhibitors,
because BaF3 cells transformed by over-
expressing p85aR348* exhibited sensitivity
to an AKT inhibitor (Cheung et al., 2014).
Ideally, a comprehensive analysis of the
sensitivity of all patient-specific PIK3R1
mutations to a large panel of targeted ther-
apies will facilitate the use of these muta-
tions as biomarkers to assign patients to
specific targeted therapies.
Altogether, these studies show that
different PIK3R1 mutants can promote
oncogenic signaling via distinct mecha-
nisms. The surprising finding from the
study by Cheung et al. (2014) is that
some of these nSH2 domain PIK3R1
mutants are neomorphic and may
induce transformation via activation of
PI3K-independent pathways. Thus, theseElsevier Inc.findings reinforce the important lesson
that we cannot assume the functional
consequences or the drug sensitivity of
poorly characterized genetic mutations.
This humbling notion is extremely impor-
tant in this evolving era in which we
are applying next-generation sequencing
to patient specimens. Although much
remains to be done, the lessons of
the IDH1/IDH2 mutations and these
PIK3R1 mutations highlight the need
for a comprehensive functional charac-
terization of patient-specific mutations
in order to refine targeted therapy
approaches.
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NF-kB protects malignant cells from death and therefore it was considered as a cancer treatment target.
However, systemic NF-kB inhibition resulted in inflammation and other undesired outcomes. In this issue
of Cancer Cell, Tornatore and colleagues solve this problem by targeting the GADD45:MKK7 module medi-
ating NF-kB-induced survival of multiple myelomas.NF-kB transcription factors are activated
by numerous inflammatory stimuli and,
in turn, induce expression of cytokines,
chemokines, secondary inflammatory
mediators, and critical immune response
genes (Figure 1). Nearly 30 years ago,
NF-kB was found to suppress apoptotic
cell death and eventually was found to
inhibit necrosis as well (Lin and Karin,
2003). Subsequently, it was noted that
NF-kB is frequently activated in solid
and hematopoietic malignancies (Staudt,
2010), giving rise to the proposal that its
protumorigenic function depends on inhi-
bition of malignant cell death, induced
by either anticancer therapies or tumor
suppressor and surveillance mechanisms
(Karin et al., 2002). The logical extension
of this hypothesis, which is supported
by vast experimental evidence, was that
inhibitors of NF-kB activity or activation
should be effective either as a stand-
alone treatment or in combination with
chemotherapy or radiation therapy in
malignancies in which NF-kB is activated
by microenvironmental stimuli or genetic
changes result in treatment resistance.
Not surprisingly, this hypothesis
kindled an intense race to develop NF-kB inhibitors, most often by targeting IkB
kinase (IKKb), a protein kinase that is
essential for NF-kB activation (DiDonato
et al., 2012). However, when such inhi-
bitors were eventually tested either in
experimental animals or in human volun-
teers, they were found to have several
undesired side effects, including inflam-
mation, immune deficiencies, and liver
damage. Whereas immune deficiencies
and liver damage were anticipated from
the study of knockout mice and reflect
the important role of NF-kB in immunity
and tissuemaintenance, the inflammatory
effect of NF-kB inhibition, observed in
both mice and human, was rather
surprising. It was found to be due, in
part, to a novel function of NF-kB in
restraining the activation of caspase 1,
the enzyme responsible for secretion of
mature IL-1b by activated macrophages
(Greten et al., 2007). Such findings
brought the clinical development of IKKb/
NF-kB inhibitors to a halt. Approaching
NF-kB inhibition from an entirely different
direction, Tornatore et al. (2014; this issue
of Cancer Cell) seem to have found
a clever and practical solution to this
problem.NF-kB mediates its survival function,
in part, by preventing the activation of
the pro-apoptotic protein kinase JNK
(De Smaele et al., 2001; Tang et al.,
2001). In certain cell lines, the mediator
through which NF-kB curtails JNK acti-
vation is the stress-induced protein
GADD45b, which interacts with the JNK-
activating kinase MKK7 and blocks its
catalytic activity (Papa et al., 2004)
(Figure 1). However, it was not entirely
clear whether GADD45b is used by NF-
kB to inhibit cell death in all types of cells
or only in cancer cells. The finding that
GADD45b-deficient mice are relatively
healthy and die of old age (Lu et al.,
2004), unlike mice lacking IKKb or RelA
that die during late embryogenesis due
to liver damage (DiDonato et al., 2012;
Lin and Karin, 2003), suggested that
GADD45b is not essential for the survival
of most normal cells. To investigate its
importance in the survival of malignant
cells, Tornatore et al. (2014) surveyed
GADD45b expression in various cancers
and found it to be highly elevated in a sub-
set of multiple myelomas (MMs), tumors
derived from plasma cells (PCs) that
are frequently associated with mutations, October 13, 2014 ª2014 Elsevier Inc. 447
